Mino-Kenudson Mari
Department of Pathology, Massachusetts General Hospital & Harvard Medical School, Boston, MA, USA.
Transl Lung Cancer Res. 2017 Oct;6(5):570-587. doi: 10.21037/tlcr.2017.07.06.
In the era of targeted therapy, predictive biomarker testing has become increasingly important for non-small cell lung cancer. Of multiple predictive biomarker testing methods, immunohistochemistry (IHC) is widely available and technically less challenging, can provide clinically meaningful results with a rapid turn-around-time and is more cost efficient than molecular platforms. In fact, several IHC assays for predictive biomarkers have already been implemented in routine pathology practice. In this review, we will discuss: (I) the details of anaplastic lymphoma kinase (ALK) and proto-oncogene tyrosine-protein kinase ROS (ROS1) IHC assays including the performance of multiple antibody clones, pros and cons of IHC platforms and various scoring systems to design an optimal algorithm for predictive biomarker testing; (II) issues associated with programmed death-ligand 1 (PD-L1) IHC assays; (III) appropriate pre-analytical tissue handling and selection of optimal tissue samples for predictive biomarker IHC.
在靶向治疗时代，预测性生物标志物检测对于非小细胞肺癌变得越来越重要。在多种预测性生物标志物检测方法中，免疫组织化学（IHC）广泛可用且技术难度较小，能够在短时间内提供具有临床意义的结果，并且比分子平台更具成本效益。事实上，几种用于预测性生物标志物的免疫组织化学检测方法已经在常规病理实践中得到应用。在本综述中，我们将讨论：（I）间变性淋巴瘤激酶（ALK）和原癌基因酪氨酸蛋白激酶ROS（ROS1）免疫组织化学检测的细节，包括多种抗体克隆的性能、免疫组织化学平台的优缺点以及各种评分系统，以设计一种用于预测性生物标志物检测的最佳算法；（II）与程序性死亡配体1（PD-L1）免疫组织化学检测相关的问题；（III）用于预测性生物标志物免疫组织化学的合适分析前组织处理和最佳组织样本的选择。
